Chemoaffinity Agents For Capturing Prostate Cancer Cells
用于捕获前列腺癌细胞的化学亲和剂
基本信息
- 批准号:7512105
- 负责人:
- 金额:$ 19.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-08-01 至 2010-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAffinityAntibodiesAttentionAvidinBe++ elementBerylliumBindingBiological AssayBiological MarkersBiosensing TechniquesBiotinBloodBlood specimenCancer DetectionCell LineCell Surface ReceptorsCell surfaceCellsChemicalsChemistryCleaved cellCore FacilityCultured CellsDetectionDevelopmentDiseaseDisseminated Malignant NeoplasmDyesElementsEndotheliumEnzyme Inhibitor DrugsEnzyme InhibitorsEnzymesFlow CytometryFluorescence MicroscopyFluorescent ProbesGlutamate Carboxypeptidase IIGoalsImageIncubatedLNCaPLabelMalignant NeoplasmsMalignant neoplasm of prostateMetastatic Prostate CancerMethodologyMicroscopeModalityModelingMolecularMonitorOutcomePC3 cell linePatientsPolyethylene GlycolsProstaticQuantum DotsReagentReporterResearchRiskSchemeSiteSlideSolidStagingStreptavidinStructureStructure of base of prostateTechnologyTestingTherapeuticTherapeutic AgentsTranslatingTumor-Associated VasculatureUniversitiesWashingtonWorkanticancer researchbasecancer cellcancer imagingclinically relevantconceptcostexperiencehigh throughput technologyin vivoinhibitor/antagonistinnovationmagnetic beadsmembernanoparticlenovelnovel diagnosticspyrrolidin-3-yl-methanesulfonic acidresearch studyscaffoldsmall moleculesuccesstargeted deliverytechnology development
项目摘要
DESCRIPTION (provided by applicant): The inhibition of prostate-specific membrane antigen (PSMA) by tight-binding small-molecule inhibitors has not been fully exploited for cell-capture and detection strategies. Our long-term goal is to develop a novel high-throughput technology to capture, image, and quantify metastatic cells that capitalizes on the potency and specific affinity of tight-binding inhibitors for cell-surface hydrolytic enzymes. The overall objective of this R21 application is to prove the concept that high-affinity irreversible inhibitors of PMSA can be employed to capture prostate cancer cells for detection and quantification. Our central hypothesis for the proposed work is that irreversible small-molecule inhibitors of PSMA tethered to a solid support through a cleavable linker can selectively capture prostate cancer cells that express PSMA for detection and quantification. We plan to test our central hypothesis and accomplish our overall objective of this application by pursuing the following specific aims: (1) develop a cell-capture platform for metastatic prostate cancer based on the structural framework of high-affinity inhibitors of PSMA and (2) develop a nanoparticle fluorescent probe to selectively label prostate cancer cells based on the core structure of high-affinity inhibitors of PSMA. The rationale for undertaking the proposed research is that, once we demonstrate that high-affinity small-molecule inhibitors of PSMA tethered to a solid support can selectively capture PSMA-expressing cells, it will serve as a proof-of-concept for the development of novel diagnostic biosensing technology for metastatic prostate cancer in a subsequent R01 proposal. The expected outcomes of this work will be the development of catch and release platforms based on immobilized inhibitors of PSMA as affinity elements will be developed to capture metastatic cancer cells from blood. Secondly, novel nanoparticle agents for detecting and quantifying selectively captured prostate cancer cells will be developed for fluorescence microscopy and flow cytometry applications. The expected positive impact of these results is that it will ultimately assist clinicians in staging prostate cancer, developing personalized therapy modalities, and monitoring treatment. These accomplishments are important, because this work allow for the development of clinically relevant cell-selecting platforms for the detection and sequestering of metastatic prostate cancer cells.
描述(由申请人提供):紧密结合的小分子抑制剂对前列腺特异性膜抗原(PSMA)的抑制作用尚未完全用于细胞捕获和检测策略。我们的长期目标是开发一种新的高通量技术来捕获、成像和量化转移细胞,该技术利用细胞表面水解酶的紧密结合抑制物的效力和特定亲和力。这项R21应用的总体目标是证明可以使用PMSA的高亲和力不可逆抑制剂来捕获前列腺癌细胞进行检测和量化的概念。我们对这项拟议工作的中心假设是,PSMA的不可逆转小分子抑制剂通过可切割连接到固体载体上,可以选择性地捕获表达PSMA的前列腺癌细胞,以进行检测和定量。我们计划验证我们的中心假设,并通过追求以下具体目标来实现这一应用的总体目标:(1)开发基于PSMA高亲和力抑制剂结构框架的转移性前列腺癌细胞捕获平台;(2)开发基于PSMA高亲和力抑制剂的核心结构选择性标记前列腺癌细胞的纳米荧光探针。开展这项拟议研究的基本原理是,一旦我们证明与固体载体连接的高亲和力PSMA小分子抑制剂可以选择性地捕获PSMA表达的细胞,它将作为后续R01提案中开发转移性前列腺癌诊断生物传感技术的概念验证。这项工作的预期结果将是开发基于PSMA固定化抑制剂的捕获和释放平台,因为将开发亲和元件来捕获血液中的转移癌细胞。其次,用于检测和定量选择性捕获的前列腺癌细胞的新型纳米颗粒试剂将被开发用于荧光显微镜和流式细胞术的应用。这些结果的预期积极影响是,它将最终帮助临床医生对前列腺癌进行分期,开发个性化治疗方式,并监测治疗情况。这些成就是重要的,因为这项工作允许开发临床相关的细胞选择平台,用于检测和隔离转移性前列腺癌细胞。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Clifford Berkman其他文献
Clifford Berkman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Clifford Berkman', 18)}}的其他基金
Near-IR Ratiometric Fluorescence Probes for Assessing Cargo Delivery to Prostate Tumors
用于评估前列腺肿瘤的货物输送的近红外比率荧光探针
- 批准号:
10328982 - 财政年份:2021
- 资助金额:
$ 19.51万 - 项目类别:
Near-IR Ratiometric Fluorescence Probes for Assessing Cargo Delivery to Prostate Tumors
用于评估前列腺肿瘤的货物输送的近红外比率荧光探针
- 批准号:
10112677 - 财政年份:2021
- 资助金额:
$ 19.51万 - 项目类别:
MMP-14 Chimeric Ligands for Targeted Imaging of Metastatic Tumors
用于转移性肿瘤靶向成像的 MMP-14 嵌合配体
- 批准号:
9035372 - 财政年份:2015
- 资助金额:
$ 19.51万 - 项目类别:
Development of a Malarial Kinase-on-Phage Screening Platform
疟疾激酶噬菌体筛选平台的开发
- 批准号:
8240362 - 财政年份:2012
- 资助金额:
$ 19.51万 - 项目类别:
Development of a Malarial Kinase-on-Phage Screening Platform
疟疾激酶噬菌体筛选平台的开发
- 批准号:
8517570 - 财政年份:2012
- 资助金额:
$ 19.51万 - 项目类别:
Chemoaffinity Agents For Capturing Prostate Cancer Cells
用于捕获前列腺癌细胞的化学亲和剂
- 批准号:
7666023 - 财政年份:2008
- 资助金额:
$ 19.51万 - 项目类别:
相似海外基金
Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections
多维开发高亲和力抗聚糖抗体以对抗致命细菌感染
- 批准号:
10549640 - 财政年份:2023
- 资助金额:
$ 19.51万 - 项目类别:
Computational modelling and simulation of antibodies to enhance binding affinity of a potential Burkholderia pseudomallei therapeutic
抗体的计算模型和模拟,以增强潜在的鼻疽伯克霍尔德氏菌治疗剂的结合亲和力
- 批准号:
2750554 - 财政年份:2021
- 资助金额:
$ 19.51万 - 项目类别:
Studentship
Affinity Biosensors for COVID-19 Antibodies
适用于 COVID-19 抗体的亲和生物传感器
- 批准号:
61319 - 财政年份:2020
- 资助金额:
$ 19.51万 - 项目类别:
Feasibility Studies
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
- 批准号:
10013588 - 财政年份:2020
- 资助金额:
$ 19.51万 - 项目类别:
Affinity maturation and property changes of single-domain antibodies through repeated immunizations.
通过重复免疫,单域抗体的亲和力成熟和性质变化。
- 批准号:
20K07009 - 财政年份:2020
- 资助金额:
$ 19.51万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening: Aiming toward total in silico design of antibodies
基于快速结构的软件可增强抗体亲和力和高通量筛选的可开发性:旨在实现抗体的全面计算机设计
- 批准号:
10603473 - 财政年份:2020
- 资助金额:
$ 19.51万 - 项目类别:
IN SILICO DESIGN OF HIGH-AFFINITY RECOMBINANT ANTIBODIES
高亲和力重组抗体的计算机模拟设计
- 批准号:
2342674 - 财政年份:2020
- 资助金额:
$ 19.51万 - 项目类别:
Studentship
Strategies for generating high affinity antibodies against Gram negative bacteria
产生针对革兰氏阴性菌的高亲和力抗体的策略
- 批准号:
10117194 - 财政年份:2020
- 资助金额:
$ 19.51万 - 项目类别:
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
- 批准号:
10115604 - 财政年份:2020
- 资助金额:
$ 19.51万 - 项目类别:
Interdisciplinary protein engineering approach to design high affinity antibodies for flaviviruses
跨学科蛋白质工程方法设计黄病毒高亲和力抗体
- 批准号:
10294224 - 财政年份:2018
- 资助金额:
$ 19.51万 - 项目类别: